These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37172552)

  • 21. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer.
    Bote H; Mesas A; Baena J; Herrera M; Paz-Ares L
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):289-300. PubMed ID: 36203360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.
    Zouein J; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody nanoparticle conjugate-based targeted immunotherapy for non-small cell lung cancer.
    Saha T; Fojtů M; Nagar AV; Thurakkal L; Srinivasan BB; Mukherjee M; Sibiyon A; Aggarwal H; Samuel A; Dash C; Jang HL; Sengupta S
    Sci Adv; 2024 Jun; 10(24):eadi2046. PubMed ID: 38875335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
    Marks JA; Wilgucki M; Liu SV; Reuss JE
    Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer.
    Zaim R; Redekop K; Uyl-de Groot CA
    J Cancer Policy; 2023 Mar; 35():100382. PubMed ID: 36592861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy in Advanced Lung Cancer.
    Huang J; Reckamp KL
    Oncology (Williston Park); 2020 Jul; 34(7):272-279. PubMed ID: 32674216
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Checkpoint inhibitors in older patients with advanced non-small cell lung cancer.
    Reale ML; Romano GD; Paolelli L; Leo S
    Crit Rev Oncol Hematol; 2023 Aug; 188():104056. PubMed ID: 37301272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Pistamaltzian NF; Georgoulias V; Kotsakis A
    Expert Rev Respir Med; 2019 May; 13(5):435-447. PubMed ID: 30869543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
    Marks S; Naidoo J
    Lung Cancer; 2022 Jan; 163():59-68. PubMed ID: 34923203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.
    Zhou J; Bao M; Gao G; Cai Y; Wu L; Lei L; Zhao J; Ji X; Huang Y; Su C
    BMC Med; 2022 Jul; 20(1):256. PubMed ID: 35902848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
    Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
    Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Application Progress of Immune Checkpoint Inhibitors 
in Oncogene-driven Advanced Non-small Cell Lung Cancer].
    Zhang T; Li B
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):188-195. PubMed ID: 33819969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
    Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
    Attili I; Passaro A; Pavan A; Conte P; De Marinis F; Bonanno L
    Crit Rev Oncol Hematol; 2017 Nov; 119():30-39. PubMed ID: 29065983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
    Reddy HG; Qin A; Kalemkerian GP
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.